Regulation And Legal
Bal Pharma Clarifies XBRL-PDF Financial Result Discrepancies
Bal Pharma responded to NSE queries regarding variations between XBRL and PDF filings for FY2026 results, attributing them to technical rounding errors.
The company refiled XBRL submissions to align w
